San Francisco — SYNARC, one of the world’s leading providers of medical image analysis services to the pharmaceutical and biotechnology industries, announced today that Dr Peter Milner has joined the company to expand and enhance the company’s rapidly growing cardiac imaging services and solutions for the clinical trial setting.
Milner, FACC, cardiologist, industry veteran and successful entrepreneur brings more than 25 years of experience in drug development and clinical trial design in cardiovascular indications with an emphasis on imaging. He co-founded three successful biotech-biopharmaceutical companies, CV Therapeutics Inc, ARYx Therapeutics and Optivia Biotechnology. CV Therapeutics was acquired by Gilead for $1.5B in 2009.
SYNARC is seeking to integrate the most up to date advances in cardiac imaging to provide state of the art services to support its client needs.
"As an experienced provider of central cardiac imaging services, SYNARC has recognized the emerging need for better definitions of cardiovascular function, structure and vessel wall biology by integrating the latest imaging modalities into the clinical trial setting. These newer modalities are revolutionizing the way cardiology is practiced and have the potential to significantly improve the process of drug approval," stated Dr. Milner. These methods are critical to the evaluation of new therapies in cardiovascular disease and can also be used to better evaluate the cardiac safety of drugs. "There are multiple drugs under development that require efficacy and safety evaluation not only by traditional endpoint, but also using high quality imaging and biomarkers which SYNARC now has available."
Aaron Timm, head of Imaging for CCBR-SYNARC stated, "Dr. Peter Milner brings a unique combination of scientific expertise, experience and understanding of needs in cardiovascular drug development with focus on modern approaches to efficacy and safety monitoring using imaging modalities. Dr. Milner’s collaboration with SYNARC further enhances our cardiovascular offering in support of our clients’ development programs."
SOURCE: CCBR-SYNARC
